OA09469A - Utilisation d'un polypeptide ayant l'activité de l'interféron gamma pour la préparation de compositions pharmaceutiques destinées au traitement de cancers primitifs de la plèvre. - Google Patents

Utilisation d'un polypeptide ayant l'activité de l'interféron gamma pour la préparation de compositions pharmaceutiques destinées au traitement de cancers primitifs de la plèvre.

Info

Publication number
OA09469A
OA09469A OA59887A OA59887A OA09469A OA 09469 A OA09469 A OA 09469A OA 59887 A OA59887 A OA 59887A OA 59887 A OA59887 A OA 59887A OA 09469 A OA09469 A OA 09469A
Authority
OA
OAPI
Prior art keywords
polypeptide
preparation
treatment
activity
pleura
Prior art date
Application number
OA59887A
Other languages
English (en)
French (fr)
Inventor
Brandely Maud
Lando Danielle
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Publication of OA09469A publication Critical patent/OA09469A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
OA59887A 1989-11-10 1990-11-09 Utilisation d'un polypeptide ayant l'activité de l'interféron gamma pour la préparation de compositions pharmaceutiques destinées au traitement de cancers primitifs de la plèvre. OA09469A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR898914780A FR2654343B1 (fr) 1989-11-10 1989-11-10 Utilisation d'un polypeptide ayant l'activite de l'interferon gamma pour la preparation de compositions pharmaceutiques destinees au traitement de cancers primitifs de la plevre.

Publications (1)

Publication Number Publication Date
OA09469A true OA09469A (fr) 1992-11-15

Family

ID=9387288

Family Applications (1)

Application Number Title Priority Date Filing Date
OA59887A OA09469A (fr) 1989-11-10 1990-11-09 Utilisation d'un polypeptide ayant l'activité de l'interféron gamma pour la préparation de compositions pharmaceutiques destinées au traitement de cancers primitifs de la plèvre.

Country Status (14)

Country Link
US (1) US5108743A (de)
EP (1) EP0427633B1 (de)
JP (1) JPH07103042B2 (de)
KR (1) KR0169975B1 (de)
AT (1) ATE96035T1 (de)
AU (1) AU645042B2 (de)
CA (1) CA2029670A1 (de)
DE (1) DE69004051T2 (de)
DK (1) DK0427633T3 (de)
FR (1) FR2654343B1 (de)
HU (1) HU206049B (de)
IL (1) IL96229A (de)
OA (1) OA09469A (de)
ZA (1) ZA907649B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2148988C1 (ru) * 1997-07-21 2000-05-20 Самойленко Игорь Иннокентьевич Усовершенствованная лекарственная форма человеческого интерферона-свеча
JP5043294B2 (ja) * 2003-09-29 2012-10-10 エー・デー・ガイストリヒ・ゾーネ・アクチェンゲゼルシャフト・フュール・ヒェーミシェ・インダストリー 中皮腫を治療する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80288A0 (en) * 1985-10-15 1987-01-30 Hoffmann La Roche Stabilized interferon compositions and their manufacture
JPH01501792A (ja) * 1986-03-17 1989-06-22 シェリング・コーポレーション γ型インターフェロンによる癌の治療
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
EP0278715A3 (de) * 1987-02-09 1989-03-08 Schering Corporation Verwendung von menschlichem Gamma-Interferon für die Behandlung von Basalzell-Karzinomen

Also Published As

Publication number Publication date
KR0169975B1 (ko) 1999-02-01
DE69004051D1 (de) 1993-11-25
IL96229A (en) 1998-04-05
JPH07103042B2 (ja) 1995-11-08
DE69004051T2 (de) 1994-03-03
FR2654343B1 (fr) 1994-08-05
IL96229A0 (en) 1991-08-16
HUT55995A (en) 1991-07-29
EP0427633B1 (de) 1993-10-20
HU206049B (en) 1992-08-28
KR910009280A (ko) 1991-06-28
AU645042B2 (en) 1994-01-06
FR2654343A1 (fr) 1991-05-17
US5108743A (en) 1992-04-28
DK0427633T3 (da) 1994-01-31
EP0427633A1 (de) 1991-05-15
ZA907649B (en) 1991-11-27
ATE96035T1 (de) 1993-11-15
JPH03188025A (ja) 1991-08-16
AU6651190A (en) 1991-05-16
CA2029670A1 (fr) 1991-05-11
HU907180D0 (en) 1991-05-28

Similar Documents

Publication Publication Date Title
EP0605442A4 (de) Rekombinante antikörper zur humanen therapie.
EP0243002A3 (en) Pharmaceutical composition for the treatment of periodontal diseases
FR2576791B1 (fr) Composition pharmaceutique a base d'erythropoietine humaine pour le traitement de l'anemie de tumeurs malignes
EP0270690A4 (de) Arzneimittel zur behandlung und prophylaxe von leber- und nierenkrankheiten.
IT1224574B (it) Fattore di attivazione di leucociti neutrofili, procedimento di preparazione, nonche' composizioni farmaceutiche che lo contengono
FR2660863B1 (fr) Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
FR2616831B1 (fr) Structure de type alveolaire pour l'enterrement de restes humains
FR2612775B1 (fr) Compositions pour la prevention et le traitement de la degenerescence cutanee
FR2550944B1 (fr) Association pharmaceutique a base d'anticorps anticellules tumorales et de conjugues cytotoxiques, appropriee notamment pour le traitement des cancers
FR2497198B1 (fr) Peptide pour le dosage de l'hormone parathyroide humaine
OA09469A (fr) Utilisation d'un polypeptide ayant l'activité de l'interféron gamma pour la préparation de compositions pharmaceutiques destinées au traitement de cancers primitifs de la plèvre.
ZA875847B (en) Pharmaceutical compositions for the treatment of occlusive vascular diseases
BE872908A (fr) Compositions pharmaceutiques pour le traitement de l'hypertension
IT8219287A0 (it) Composizione per la pulizia e l'igiene dentaria.
OA08609A (fr) Composition pharmaceutique pour le traitement des infections bactériennes.
EP0222912A4 (de) Mittel zur behandlung von arteriosklerose.
GR3005231T3 (de)
BE881763A (fr) Nouvelles compositions pharmaceutiques utilisables pour le traitement de l'hypertension
IT8467183A1 (it) Composizione farmaceutica per la profilassi ed il trattamento dell'arteriosclerosi.
OA09530A (fr) Utilisation d'un polypeptide ayant l'activité de l'interleukine 2 humaine pour la préparation de compositions pharmaceutiques destinées au traitement des pneumothorax
FR2608597B1 (fr) Compositions pharmaceutiques contenant de l'acetylsalicylate de lysine
FR2598616B1 (fr) Composition pharmaceutique destinee au traitement des phenomenes d'inflammation chez les mammiferes
FI874823A0 (fi) Farmaceutisk komposition foer anvaendning mot hypertension och kongestiv hjaertinsufficiens.
MA21630A1 (fr) Compositions pour le traitement de leishmanioses .
IT8622051A0 (it) Composizioni farmaceutiche adattivita' cicatrizzante.